Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

fludarabine phosphate 12Mycophenolic Acid 12Cyclophosphamide 11Whole-Body Irradiation 10Cyclosporine 10Cord Blood Stem Cell Transplantation 9Peripheral Blood Stem Cell Transplantation 7Busulfan 6Tacrolimus 5Radiotherapy 5fludarabine 4Antilymphocyte Serum 4Thiotepa 3Methotrexate 3Melphalan 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Etoposide 3Cyclosporins 3sargramostim 2merphos 2Methylprednisolone 2Decitabine 2Cytarabine 2vatalanib 1poly ICLC 1lintuzumab 1entinostat 1Vorinostat 1Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anemia, Refractory × lintuzumab × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡